Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer

Charles M. Rudin, Gini F. Fleming, Sridhar Mani, Walter M. Stadler, Philip Schumm, Mark J. Ratain, Jon Holmlund, Brett P. Monia, Joseph F. Johnston, Richard Geary, Rosie Z. Yu, T. Jesse Kwoh, F. Andrew Dorr

Research output: Contribution to journalArticlepeer-review

129 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences